ARQT Arcutis Biotherapeutics Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARQT
  4. Earnings
?
Relative Growth: Rel. Growth: 93
Relative Strength: Rel. Strength: 61
Relative Valuation: Rel. Valuation: 22
Relative Profitability: Rel. Profitability: 88

EPS in 2026 (TTM): $0.21

Last Report Period Date: Jun 30, 2026

Based on the company's latest reports for June 2026, the current EPS (TTM) is $0.21. Arcutis Biotherapeutics's earnings per share in 2025 came in at -$0.13, marking an increase from -$1.16 in 2024. For the quarterly period ending on Jun 30, 2026, ARQT's earnings per share was $0.11.

ARQT earnings history

Historical annual and quarterly earnings per share (EPS) data for Arcutis Biotherapeutics
EPS (TTM)
$0.21
EPS Growth YoY (Quarterly)
184.6%
EPS (Quarterly)
$0.11
EPS Growth (Quarterly)
222.2%

Arcutis Biotherapeutics had an yealy EPS of -$0.13, marking an increase of 88.8% from -$1.16 recorded in 2024. The quarterly EPS for the period ending Jun 30, 2026, was $0.11, marking a 184.6% increase compared to the same quarter last year. ARQT's TTM EPS is $0.21 as of June 2026. Arcutis Biotherapeutics's EPS for 2024 was -$1.16, a 69.3% rise from 2023.

ARQT EPS vs price chart

ARQT EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
184.6%
EPS growth YoY
88.8%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Over the past 12 months, Arcutis Biotherapeutics has recorded an earnings per share growth of 184.6% (YoY, quarterly).

ARQT Earnings Waterfall

Breakdown of revenue, profit and net income for Arcutis Biotherapeutics

ARQT Earnings vs Peers

What are the earnings of ARQT compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
ORMP Oramed Pharmaceuticals Inc 1.17 418.8% N/A N/A
OMER Omeros Corp 10.01 98.1% N/A N/A
ARQT Arcutis Biotherapeutics Inc 112.71 88.8% N/A N/A
OLMA Olema Pharmaceuticals Inc N/A 15% N/A N/A
VIVS VivoSim Labs Inc. N/A -214.7% N/A N/A
ORIC Oric Pharmaceuticals Inc N/A 19.7% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.